Indonesia and Russia are engaging in discussions to explore pharmaceutical technology transfers aimed at enhancing local medicine production and reducing dependency on imports. The initiative involves Indonesia’s Food and Drug Authority (BPOM) and Russia’s Ministry of Industry and Trade, with key discussions led by BPOM’s Taruna Ikrar and Russian Deputy Minister Alexey Vladimirovich Gruzdev.
The talks focus on several areas, including pharmaceutical manufacturing, quality inspections, and the use of digital technologies to improve product safety and traceability. Critical to Indonesia’s interests is the expansion of domestic production of diabetes treatments, such as insulin and glucagon-like peptide-1 (GLP-1) medicines, which are essential for improving access to healthcare products.
Both nations identified potential areas for cooperation in cancer treatments, monoclonal antibodies, antiviral medicines, and advanced biotechnology products. Russian companies have shown interest in transferring technology and possibly establishing manufacturing facilities in Indonesia, especially for insulin, oncology medicines, and biotechnology products. The Russian delegation noted that several Russian pharmaceutical companies have already submitted product registration documents to BPOM.
The discussions also revisited existing cooperation frameworks, including Good Manufacturing Practice (GMP) inspections, technical training, and information sharing. A memorandum of understanding is being finalized to create a structured framework for deeper collaboration. Additionally, Russia proposed mutual recognition of GMP certificates to streamline regulatory procedures, a proposal that requires further dialogue to ensure compatibility between both countries’ regulatory systems.
To bolster Indonesia’s inspection capabilities, Russia offered technical training, which includes virtual reality-based simulations to prepare inspectors for pharmaceutical manufacturing assessments. The discussions also encompassed digital regulatory systems and supply-chain monitoring as both sides expressed interest in continuing negotiations and expanding cooperation through further meetings and site visits to pharmaceutical manufacturing facilities.